| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 13, 2026Next | Q3 2026 | — | 2.95 | 25.6 B |
Sep 2, 2026
Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...
Sep 1, 2026
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.
Aug 31, 2026
NEW BRUNSWICK, N.J., August 31, 2026--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi
One of J&J's investments stands head-and-shoulders above the rest.
The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials
Aug 30, 2026
Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the yield tier you choose can demand nearly three times as much capital for the same income target. A 79-year-old widow with fixed expenses and no room for error found a middle path most retirees overlook entirely.
Aug 29, 2026
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.
Johnson & Johnson stock has delivered an 81.9% gain over the past three years, yet the valuation picture is split between an intrinsic value estimate that points to upside and market multiples that lean the other way. With recent approvals in key therapies alongside ongoing legal exposure, investors are weighing how much of Johnson & Johnson’s story is already reflected in the current share price. The 81.9% return over three years signals that Johnson & Johnson has rewarded longer term...
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]
